Global Virology Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Procedure;

Cell Culture Method, Specific Antibodies Detection, Antigen Detection, Virus Nucleic Acid Detection, Gene Sequencing, and Hemagglutination Assays.

By Diagnosis Test;

Hepatitis B, Hepatitis C, HIV, Human Papillomavirus (HPV), and Other Tests.

By Method;

Immunoprophylaxis, Active Prophylaxis (Vaccines, Passive Prophylaxis, Antiviral Chemotherapy and Interferonos (Cytokines).

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn688695059 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Virology Testing Market (USD Million), 2021 - 2031

In the year 2024, the Global Virology Testing Market was valued at USD 5,013.57 million. The size of this market is expected to increase to USD 8,566.79 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.0%.

The Global Virology Testing Market stands as a cornerstone of modern healthcare, offering indispensable tools and technologies for the detection, diagnosis, and management of viral infections. This introduction provides a comprehensive overview of the market, encompassing the diverse array of virology testing solutions, applications, and stakeholders driving innovation and progress in the field of viral diagnostics.

Viral infections represent a significant burden on public health worldwide, ranging from common respiratory viruses to emerging pathogens with pandemic potential. Virology testing plays a critical role in identifying viral pathogens, guiding clinical decision-making, and implementing public health measures to prevent and control infectious diseases. From traditional methods to cutting-edge molecular diagnostics, the Global Virology Testing Market encompasses a broad spectrum of testing solutions designed to meet the evolving needs of healthcare providers, researchers, and public health authorities.

At the forefront of the Global Virology Testing Market are diagnostic technologies that enable the rapid and accurate detection of viral nucleic acids, antigens, and antibodies in clinical specimens. Molecular diagnostic assays, such as polymerase chain reaction (PCR), real-time PCR, and nucleic acid sequencing, offer high sensitivity and specificity for detecting viral genomes, facilitating the diagnosis of acute infections, monitoring of viral load, and surveillance of viral variants. These molecular testing platforms play a crucial role in diagnosing respiratory viruses, bloodborne viruses, sexually transmitted infections, and emerging infectious diseases, providing essential information for patient management and infection control.

In addition to molecular diagnostics, the Global Virology Testing Market encompasses a variety of serological assays for detecting viral antigens and antibodies in patient samples. Enzyme-linked immunosorbent assays (ELISA), lateral flow assays, and chemiluminescent immunoassays (CLIA) enable the detection of specific viral proteins and host immune responses, aiding in the diagnosis of acute and past infections, seroprevalence studies, and vaccine efficacy monitoring. Serological testing is particularly valuable for detecting antibodies against viruses such as human immunodeficiency virus (HIV), hepatitis viruses, and emerging pathogens such as SARS-CoV-2, providing insights into immune status and population-level immunity.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Procedure
    2. Market Snapshot, By Diagnosis Test
    3. Market Snapshot, By Method
    4. Market Snapshot, By Region
  4. Global Virology Testing Market Trends
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Molecular Diagnostics
        2. Point-of-Care Testing (POCT)
        3. Serological Assays
        4. Pandemic Preparedness
      2. Restraints
        1. Regulatory Challenges
        2. Limited Access to Testing
        3. Resource Constraints
        4. Cost Constraints
      3. Opportunities
        1. Emerging Markets Expansion
        2. Technological Innovations
        3. Personalized Medicine Approaches
        4. Increased Funding for Research
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Virology Testing Market, By Procedure, 2021 - 2031 (USD Million)
      1. Cell Culture Method
      2. Specific Antibodies Detection
      3. Antigen Detection
      4. Virus Nucleic Acid Detection
      5. Gene Sequencing,
      6. Hemagglutination Assays
    2. Global Virology Testing Market, By Diagnosis Test, 2021 - 2031 (USD Million)
      1. Hepatitis B
      2. Hepatitis C
      3. HIV
      4. Human Papillomavirus (HPV),
      5. Other Tests
    3. Global Virology Testing Market, By Method, 2021 - 2031 (USD Million)
      1. Immunoprophylaxis
      2. Active Prophylaxis (Vaccines
      3. Passive Prophylaxis
      4. Antiviral Chemotherapy
      5. InterferonÕs (Cytokines)
    4. Global Virology Testing Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia/New Zealand
        5. South Korea
        6. ASEAN
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
      5. Rest of Middle East & Africa
        1. Latin America
        2. Brazil
        3. Mexico
        4. Argentina
        5. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Boehringer Ingelheim International GmbH.,
      2. Merck and Co. Inc,
      3. Novartis AG
      4. Abbott
      5. GlaxoSmithKline plc
      6. Siemens Healthcare Private Limited
      7. Johnson & Johnson Services, Inc.,
      8. AstraZeneca
  7. Analyst Views
  8. Future Outlook of the Market